Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 17, 2021 - Issue 1
Submit an article Journal homepage
527
Views
4
CrossRef citations to date
0
Altmetric
Original Research

‘Real-world’ effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis

Kenneth M. Faulknera Connell School of Nursing, Boston College William F, Chestnut Hill, MA, USA;b School of Nursing, Stony Brook University, Stony Brook, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2434-4890View further author information
ORCID Icon,
Karen MacDonaldc Division of Research, Matrix45, Tucson, AZ, USAORCID Iconhttps://orcid.org/0000-0002-4568-9783View further author information
ORCID Icon,
Ivo Abrahamc Division of Research, Matrix45, Tucson, AZ, USA;d Health Outcomes and PharmacoEconomic Research, University of Arizona Center For, Tucson, AZ, USA;e Pharmacy and College of Medicine, University of Arizona College Of, Tucson, AZ, USAORCID Iconhttps://orcid.org/0000-0003-0490-4421View further author information
ORCID Icon,
Abdulaziz Alhossanf College of Pharmacy, King Saud University, Riyadh, Saudi ArabiaORCID Iconhttps://orcid.org/0000-0001-5849-6756View further author information
ORCID Icon &
Christopher S. Leea Connell School of Nursing, Boston College William F, Chestnut Hill, MA, USAORCID Iconhttps://orcid.org/0000-0002-2510-4071View further author information
ORCID Icon
Pages 73-83 | Received 06 Aug 2020, Accepted 24 Nov 2020, Published online: 14 Dec 2020

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Deniz Tugay, Mehmet Top, Ömür Aydin, Sevim Bavbek, Ebru Damadoğlu, Ferda Öner Erkekol, Ilkay Koca Kalkan, A. Fuat Kalyoncu, Gül Karakaya, I. Kivilcim Oğuzülgen, Haluk Türktaş & Ivo Abraham. (2023) Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey. Journal of Medical Economics 26:1, pages 720-730.
Read now
Francesco Menzella, Matteo Fontana, Marco Contoli, Patrizia Ruggiero, Carla Galeone, Silvia Capobelli, Anna Simonazzi, Chiara Catellani, Chiara Scelfo, Claudia Castagnetti, Francesco Livrieri & Nicola Facciolongo. (2022) Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life. Journal of Asthma and Allergy 15, pages 505-515.
Read now

Articles from other publishers (2)

V. V. Naumova, E. K. Beltyukov, D. V. Kiseleva, A. A. Shtanova & D. A. Stepina. (2023) Omalizumab: a quarter of a century in the fight against T2-inflammatory diseases of upper and lower respiratory tract. Meditsinskiy sovet = Medical Council:20, pages 68-83.
Crossref
Julio Delgado, Ana Navarro, Francisco Javier Álvarez-Gutiérrez, Carolina Cisneros & Javier Domínguez-Ortega. (2023) Necesidades no cubiertas en asma alérgica grave. Open Respiratory Archives 5:4, pages 100282.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.